


CD161

Cat. No.:	HY-124596
CAS No.:	1627716-22-6
Molecular Formula:	C ₂₆ H ₂₁ N ₅ O ₂
Molecular Weight:	435.48
Target:	Epigenetic Reader Domain
Pathway:	Epigenetics
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	CD161 (NKR-P1A) is a potent, selective and orally bioavailable bromodomain and extra-terminal (BET) bromodomain inhibitor with an IC ₅₀ s of 28.2 nM and 7.2 nM for BRD4 BD1 and BRD4 BD2, respectively. CD161 has good anticancer activity ^[1] .								
IC₅₀ & Target	IC ₅₀ : 28.2 nM (BRD4 BD1) and 7.2 nM (BRD4 BD2) ^[1]								
In Vitro	<p>CD161 (NKR-P1A) has K_is of 8.2 nM and 1.4 nM for BRD4 BD1 and BRD4 BD2, respectively^[1].</p> <p>CD161 (30-3000 nM; 1 hours) is very effective in inducing rapid down-regulation of c-Myc at as early as the 1 h time point and in a dose-dependent manner^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Western Blot Analysis^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>MV4;11 leukemia cells.</td> </tr> <tr> <td>Concentration:</td> <td>30, 100, 300, 1000, 3000 nM</td> </tr> <tr> <td>Incubation Time:</td> <td>1 hours</td> </tr> <tr> <td>Result:</td> <td>Induced rapid down-regulation of c-Myc at as early as the 1 hours time point and in a dose-dependent manner.</td> </tr> </table>	Cell Line:	MV4;11 leukemia cells.	Concentration:	30, 100, 300, 1000, 3000 nM	Incubation Time:	1 hours	Result:	Induced rapid down-regulation of c-Myc at as early as the 1 hours time point and in a dose-dependent manner.
Cell Line:	MV4;11 leukemia cells.								
Concentration:	30, 100, 300, 1000, 3000 nM								
Incubation Time:	1 hours								
Result:	Induced rapid down-regulation of c-Myc at as early as the 1 hours time point and in a dose-dependent manner.								
In Vivo	<p>CD161 (NKR-P1A) (po; 20, 40 mg/kg/day; 45 days) achieves essentially complete tumor growth inhibition^[1].</p> <p>CD161 (5 mg/kg (iv), 25 mg/kg (po); 0-24 hours) has the t_{1/2} of 2.4 hours (iv) and 2.9 hours (po) for rat; the C_{max} of 7333 ng/mL (po) for rat. The t_{1/2} of mice is 0.5 hours (iv) and 1.60 hours (po); the C_{max} of mice is 983.1 ng/mL (po) ^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Dorsal side of severe combined immunodeficient (SCID) mice^[1]</td> </tr> <tr> <td>Dosage:</td> <td>20, 40 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Po; daily; 45 days</td> </tr> <tr> <td>Result:</td> <td>Achieved essentially complete tumor growth inhibition.</td> </tr> </table>	Animal Model:	Dorsal side of severe combined immunodeficient (SCID) mice ^[1]	Dosage:	20, 40 mg/kg	Administration:	Po; daily; 45 days	Result:	Achieved essentially complete tumor growth inhibition.
Animal Model:	Dorsal side of severe combined immunodeficient (SCID) mice ^[1]								
Dosage:	20, 40 mg/kg								
Administration:	Po; daily; 45 days								
Result:	Achieved essentially complete tumor growth inhibition.								

Animal Model:	Rat or mice ^[1]
Dosage:	5 mg/kg (iv), 25 mg/kg (po) for rat and mice (Pharmacokinetic Study)
Administration:	Iv and po; 0, 5, 15, 30 mins, and 1, 2, 4, 6, 8, 24 hours
Result:	The $t_{1/2}$ of rat is 2.4 hours (iv) and 2.9 hours (po); the C_{max} of rat is 7333 ng/mL (po). The $t_{1/2}$ of mice is 0.5 hours (iv) and 1.60 hours (po); the C_{max} of mice is 983.1 ng/mL (po) ^[1] .

REFERENCES

[1]. Zhao Y, et al. Structure-Based Discovery of 4-(6-Methoxy-2-methyl-4-(quinolin-4-yl)-9H-pyrimido[4,5-b]indol-7-yl)-3,5-dimethylisoxazole (CD161) as a Potent and Orally Bioavailable BET Bromodomain Inhibitor. J Med Chem. 2017 May 11;60(9):3887-3901.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA